View the official press release distributed through PR Newswire.
The emerging leader in liquid biopsy sample prep will have the latest automation and kits at exhibit booth #1321.
VANCOUVER, BC, Oct. 17, 2024 – nRichDX®, best known for its Revolution Sample Prep System™ for liquid biopsy, will display its latest products, present new data, and exhibit at the Association for Molecular Pathology (AMP) Annual Meeting 2024.
The meeting is November 19-23 at the Vancouver Convention Centre in Vancouver, British Columbia, Canada. The meeting is devoted to exploring and recognizing the latest discoveries in molecular pathology and precision medicine.
nRichDX will exhibit in booth #1321, and its solutions will be used in at least three technical posters. The exhibits open at 11:15 AM on Thursday, November 21 and close at 1:30 PM on Saturday, November 23.
nRichDX at the AMP Annual Meeting
Automation, new cartridges, and collaborative research.
Visit nRichDX at booth #1321
Revolution Plus™ Sample Prep System on display
Preview of the Revolution Pro™ instrument planned for 2025
nRichDX solutions featured in at least three technical posters
Addressing the Upstream Sample Preparation Challenge
AMP Meeting attendees working in liquid biopsy and the extraction of analytes including ctDNA, ctRNA, cell-free total nucleic acid (cfTNA), and the enrichment of circulating tumor cells (CTCs) were encouraged to visit the nRichDX booth to see the latest liquid biopsy sample prep solutions.
The company highlighted how extracting higher yields of these analytes can increase assay performance through better sensitivity and earlier detection of targeted oncology markers.
“Sample prep yield has been called the critical bottleneck in liquid biopsy - with poor yields primarily responsible for assay failures due to poor sensitivity, false negatives, and QNS errors. Existing sample prep methods are a big part of liquid biopsy's sensitivity problem.”
“Revolution Sample Prep is engineered to solve liquid biopsy's sensitivity problem by delivering higher yields of rare analytes with a simpler, scalable workflow. I particularly look forward to meeting AMP 2024 attendees looking for liquid biopsy solutions beyond the status quo,” Curtis said.
Revolution Plus™ and Revolution Pro™
The nRichDX booth will feature the Revolution Plus™ instrument and a preview of the Revolution Pro™ instrument being introduced in 2025.
Both automated sample prep solutions exclusively process nRichDX's unique nRicher™ Cartridges.
The new nRicher Cartridges have the broadest input sample volume range of any commercially available kit, from as little as 1 mL up to 100 mL in a single extraction, eliminating the tedious and yield-lowering sample transfer, pooling, preconcentration, and re-elution steps often required by other sample prep methods.
Explore the Revolution PlatformResearch Featuring nRichDX Solutions
At least three posters planned for the meeting included nRichDX solutions:
Enhanced Extraction and Preservation of Circulating Cell-Free RNA from 50 mL Cell-Free Urine , presented in collaboration with Agilent Technologies
The Mutational Landscape of Circulating Tumor Cells in Pancreatic Cancer , presented in collaboration with Dartmouth Hitchcock Medical Center
Clinical Validation of Cell-free DNA (cfDNA) Extraction from Whole Blood Plasma using the nRichDX® Revolution Max 20 Kit and Sample Prep System , presented in collaboration with Dartmouth Hitchcock Medical Center
About nRichDX
nRichDX® provides kits and automated solutions for isolating cfDNA, cfRNA, and CTCs. The patented Revolution Sample Prep System™ is engineered specifically for liquid biopsy applications and isolating analytes from blood, plasma, urine, and other biofluids.
It is the first and only high-yield, high-recovery, IVD-labeled sample prep platform to process from as little as 1 mL to 100 mL in a single extraction using the company's patented Revolution nRicher™ Cartridges.
Unlike other methods, Revolution sample prep doesn't require yield-lowering sample preconcentration, eluate pooling, sample transfer, or sample re-elution steps.
nRichDX helps solve one of precision medicine's greatest problems: inaccurate or incomplete diagnostic results for liquid biopsy-based applications due to insufficient analyte.
Learn more about nRichDX